Studies

Question 1

RTOG 0522

Answer 1

Phase III Randomized trial
Cisplatin + RT vs Cisplatin-Cetuximab + RT
940 pts, Locally advanced H&N ca
Stage III/IV, T3/T4, M0
SCC of oropharynx, hypopharynx or larynx
.
.
.
End point: PFS, FU: 3.8 years
.
.
No improvement in OS, PFS, LRC or DM
.
.
3 year
OS: 72.9% vs 75.8%
PFS: 61.2% vs 58.9%
LRF: 19.9% vs 25.9%
DM: 13.0% vs 9.7%

Question 2

OS benefit of concurrent chemotherapy

Answer 2

Oral Cavity = 8.9%
Oropharynx = 8.1%
Larynx = 5.4%
Hypopharynx = 4%

Question 3

Bonner Trial

Remember as Bonner sucked! Cetuximab!

Answer 3

RT alone vs RT + Cetuximab
Pts who got **Cetuximab + RT **using boost showed largest improvement in survival
Oropharynx subsite had the greatest improvement in LRC & OS

Question 4

General H&N Staging HPV-ve only

Answer 4

Question 5

RTOG 90-03

Answer 5

Q: Investigating role of altered fractionation for locally advanced H&N SCCa.
.
.
.
4 arms
1) Std fx 70Gy in 35 fxs in 7 weeks
2) Hyperfx 81.6Gy BID 5 days/week in 7 weeks
3) Accelerated split course 67.2/1.6Gy BID with 2 weeks break in 6 weeks
4) Accelerated with delayed boost 72Gy in 6 weeks QD and last 12 days BID